Vedolizumab for teens with moderate to severe Crohn's
Treatments studied
Part of Digestive system clinical trials.
This trial tests vedolizumab to treat children and teens with moderate to severe Crohn’s disease when standard treatments haven’t worked or caused side effects. It may help reduce gut inflammation and symptoms and help some patients stay healthier over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe Crohn’s disease that is not improving (or you can’t tolerate it) with standard treatments.
- You weigh at least 10 kg at the time you join.
- Crohn’s must have been diagnosed at least 1 month ago, and recent tests show the disease is moderately to severely active.
- You must have tried at least one key prior treatment (steroids, immune medicine like azathioprine or methotrexate, or biologic anti-TNF like infliximab or adalimumab) and it failed or caused side effects.
- If your colitis has lasted many years or affects the left side, you must have a recent surveillance colonoscopy showing no concerning changes.
- You must be up to date on childhood vaccines for your country.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
Hear when a new Crohn's Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.